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1 |  INTRODUCTION
Despite the advances in cancer research and the investments 
in sophisticated equipment, cancer is still responsible for al-
most one in every six deaths globally, according to the World 
Health Organization, with more than 14 million new cases 
every year and a projection of over 26 million by 2030 (Thun 
et al., 2010).
Among all types of cancer, breast cancer remains one 
of the most common causes of cancer-related death, with 
1.7 million new cases annually, comprising 25% of all cancer 
types (Ghoncheh et al., 2016). Its heterogeneous nature oc-
curs as a result of both intertumor and intratumor variations 
resulting in a decrease of detection and diagnosis accuracy, as 
well as of treatment effectiveness (Almendro & Fuster, 2011; 
Song et al., 2016; Sørensen et al., 2017).
While the intertumor heterogeneity alone demands for 
personalized diagnosis and treatment, intratumor heteroge-
neity represents a tremendous challenge for treatment se-
lection (Almendro & Fuster,  2011; Song et  al.,  2016). For 
example, estrogen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor receptor-type 2 (HER2) 
expression varies in different regions within the same tumor, 
as well as the microenvironment components like stromal 
cells and extracellular matrix, causing resistance to therapies 
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Breast cancer diagnosis remains a challenge, mostly due to its heterogeneity. This re-
ality translates in delayed treatments, increasing treatment aggressiveness and lower 
chances of overall survival. The conventional detection techniques, although be-
coming increasingly sophisticated each year, still lack the ability to provide reliable 
conclusions without being time consuming, expensive, and uncomfortable for the pa-
tients. The identification of novel biomarkers for breast cancer research is therefore 
of utmost relevance for an early diagnosis. Moreover, breast cancer-specific peptide 
moieties can be used to develop novel targeted drug delivery systems. In this work, 
we used phage display to identify a novel peptide with specificity to the SK-BR-3 
breast cancer cell line. Cytometry assays confirmed its specificity, while bioinfor-
matics and docking studies predicted the potential biomarkers at the SK-BR-3 cells' 
surface. These findings can be potentially useful in the clinical context, contribut-
ing to more specific and targeted therapeutic solutions against HER2-positive breast 
cancer subtypes.
K E Y W O R D S
biomarker, breast cancer, CTGNQAAFC, phage display, SK-BR-3
894 |   CLÁUDIA PEREIRA Et AL.
in some patients and, therefore, substantially affecting the ef-
fectiveness of the treatment (Almendro & Fuster, 2011; Song 
et al., 2016).
Conventional detection techniques, like mammography, 
magnetic resonance imaging, and ultrasounds, as well as bi-
opsies to detect ER, PR, and HER2 expression and molecu-
lar profiling with microarrays, have enabled the distinction 
between different breast cancer types (American Cancer 
Society, 2016; Le Du et  al.,  2013; Nobrega et  al.,  2016). 
Still, the diagnosis involves several invasive tests that de-
mand time and cause patient discomfort in order to narrow 
down the chances of false positives and false negatives, and 
to accurately apply the most appropriate treatment (Hassan 
& El-Shenawee, 2011). Hence, finding new specific target-
ing moieties to diagnose each breast cancer subtype at early 
stages without the need of invasive tests remains an unmet 
need (Larimer & Deutscher, 2014; Sauter, 2017).
The search for novel recognition elements has been, 
among other strategies, falling into the use of peptides since 
they can be easily synthesized and modified to improve sta-
bility, solubility, and tissue penetration (Silva et al., 2016). 
Peptides can be selected by evolutionary screening tech-
niques, such as phage display. This in vitro methodology 
allows the identification of ligands for proteins and other 
macromolecules. Libraries of phage-displayed peptides 
are physically linked to their encoding nucleic acid (Bazan 
et al., 2012), allowing selection of binding partners through 
iterative and repeated cycles of in vitro panning and ampli-
fication, followed by DNA sequencing (Liu et  al.,  2016). 
Furthermore, phage display has the advantage of likely 
retaining the native structure and functional conformation 
of proteins without requiring any previous knowledge of 
the molecular composition at the site of interest, provid-
ing a rapid, simple, and economic identification of pep-
tide ligands for various target molecules or structures (Li 
et al., 2017). In addition, peptides can be labeled with the 
appropriate moieties or conjugated with nanoparticles, li-
posomes, anti-cancer drugs for early imaging diagnosis 
and targeted therapy (Li et al., 2017; Nobrega et al., 2016). 
Although most phage display experiments suffer from am-
plification bias because it imparts unintended selection 
pressure beyond binding to the desired target, this disad-
vantage can be overcome through a simple method that 
uses a pRARE plasmid extracted from Rosetta cells and 
transformed into Escherichia coli cells. This decreases the 
chances of amplification bias, increasing the uniformity of 
phage production in a random library (Umlauf et al., 2015).
Herein, in this work, we identified a novel peptide, Pep1-
CTGNQAAFC, homing the HER2-positive breast cancer cell 
line SK-BR-3 using a commercial phage display library. The 
peptide herein identified was characterized for binding and 
selectivity. Bioinformatic tools were used to identify poten-
tial cell surface targets to which this peptide binds, envisaging 
their future application as a new targeting system for breast 
cancer diagnostic.
2 |  METHODS AND MATERIALS
2.1 | Cell culture, media and buffers
The human breast cancer cell line SK-BR-3 (ATCC HTB-30; 
provided by Dr. Ana Preto from the Centre of Molecular and 
Environmental Biology [CBMA-University of Minho]) and 
the BT-474 (ATCC HTB-20; provided by Dr. Amelia Silva 
from the University of Trás-os-Montes and Alto Douro) were 
grown in Dulbecco's Modified Eagle's Medium (DMEM, 
Biochrom) and DMEM:HAMs F-12, respectively, supple-
mented with 10% (v/v) fetal bovine serum (FBS, Biochrom) 
and 1% (v/v) of penicillin–streptomycin (Biochrom). The 
human non-tumorigenic mammalian cell line MCF-10-2A 
(ATCC CRL-10781) obtained from ATCC was routinely cul-
tivated in a 1:1 solution of DMEM:HAMs F-12 medium sup-
plemented with 5% horse serum (Merck Millipore), 20 ng/
ml epidermal growth factor (Merck Millipore), 100  ng/ml 
cholera toxin (Sigma-Aldrich), 0.01 mg/ml insulin (Sigma-
Aldrich), 500  ng/ml hydrocortisone, 95% (Sigma-Aldrich) 
and 1% penicillin–streptomycin. Cells were maintained at 
37ºC with 5% CO2. Sub-culturing was performed when the 
cell culture reached 80% of confluence. The cells were washed 
using phosphate-buffered saline 1× pH 7.4 (PBS 1×:137 mM 
NaCl [Nzytech], 2.7 mM KCl [ChemLab], 10 mM Na2HPO4 
[Scharlau] and 2 mM KH2PO4 [Panreac]) and detached using 
Trypsin/EDTA solution [Biochrom].
2.2 | In vitro biopanning methodology
A commercial phage display library, Ph.D.TM – C7C li-
brary purchased from New England BioLabs (NEB), was 
used. The library consists of 1.2 × 109 electroporated se-
quences and a concentration of 1  ×  1013 plaque-forming 
units per milliliter (PFUs/ml). An adaptation of a biopan-
ning protocol described by Giordano et al. (2001) using SK-
BR-3 cell line as target was followed as stated elsewhere 
(Nobrega et al., 2016; Silva et al., 2016). This procedure 
was repeated for a total of four rounds of panning. A final 
counter-selection step was included using the non-tumori-
genic MCF-10-2A cell line. Due to titer losses, the phage 
pool was amplified in the last two rounds using a modified 
E. coli JM109+ strain (Silva et al., 2016) which has a plas-
mid (pRARE) that encodes for six low abundance tRNAs, 
reducing the amplification bias (Umlauf et al., 2015). The 
phage titer was determined for each round of selection 
using the double layer agar technique in LB plates (25 g/L 
Luria Bertani broth [Nzytech] with 20  g/L agar [VWR]) 
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supplemented with 0.25 mM IPTG (Nzytech) and 0.05 g/L 
X-gal (Nzytech). The number of transducing units was cal-
culated by counting the blue plaques after overnight incu-
bation at 37°C.
2.3 | Selection and amplification of 
positive clones
The ssDNA of individual clones was extracted using a stand-
ard protocol (NEB:Ph.D.TM). Briefly, the iodide buffer 
(10  mM Tris-HCl, 1  mM EDTA, and 4  M NaI [Sigma-
Aldrich], pH 8.0) and ethanol were used to precipitate the 
DNA. The final pellets were resuspended in 30  µl of TE 
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0), quantified 
by Nanodrop 1000, and confirmed by electrophoresis in TAE 
1× buffer in a 2% gel at 90 V for 50 min.
The amplification of each selected clone was carried out 
by PCR using 5′- TTAACTCCCTGCAAGCCTCA-3′ as the 
forward primer and 5′- CCCTCATAGTTAGCGTAACG -3′ 
as the reverse primer. The PCRs were prepared using the 
MasterMixS from peqGOLD and 10 ng of phage DNA in a 
20 µl reaction final volume, with the following conditions: 
35 cycles of 30 s of denaturation at 95°C, 30 s of annealing 
at 60.5°C and 1 min of extension at 72°C. The amplifications 
were then confirmed by electrophoresis in TAE 1× buffer in 
a 2% gel at 90 V for 50 min.
2.4 | DNA sequencing and insert analysis
The DNA products obtained from amplification were pre-
pared for sequencing using Illustra ExoProStar. Sequencing 
was carried out by GATC Biotech with the forward primer 
5′- TTAACTCCCTGCAAGCCTCA -3′. Vector NTI (Vector 
NTI Advance, version 11.5, Invitrogen) was used to analyze 
the correct insertion of the peptides, taking into considera-
tion that the displayed peptides should be expressed at the 
N-terminus of pIII, followed by the Gly–Gly–Gly–Ser spacer 
and wild-type pIII sequence.
2.5 | Binding assays
Bacteriophage labeling was carried out as previously de-
scribed (Silva et al., 2016). Briefly, around 1 × 1010 PFUs/
ml of phage suspension were precipitated with 20% poly-
ethylene glycol (PEG) 8,000/2.5  M NaCl and resuspended 
in 0.1 M NaHCO3 pH 8.5 (Sigma) and then incubated with 
Alexa Fluor 488 tetrafluorophenyl ester (Alfagene), previ-
ously dissolved in anhydrous DMSO. After incubation, the 
labeled phages were recovered by centrifugation at 7,500 g 
for 5 min at 4°C using amicon-15 centrifugal filter units with 
a nominal molecular weight limit of 50 kDa (Merck). Final 
upper solution was resupended in 1 ml of PBS.
Binding assays were characterized based on selectivity 
and specificity of the phages against the target cell line, SK-
BR-3, as well as BT-474 and MCF-10-2A cell lines, through 
cytometry. Briefly, 1 × 105 cells were washed with PBS 1× 
and blocked with a 3% BSA solution in PBS 1× for 1 hr at 
4°C. Afterward, the cells were washed with PBS 1× with 
Tween-20 (PBST, PBS 1× with 0.1% (v/v) Tween 20) and 
incubated with the labeled phages for 1 hr at 4°C. The cells 
were then washed with PBST and suspended in PBS 1× for 
cytometry analysis with the EC800TM flow cytometer ana-
lyzer (Sony Biotechnology), where a total of 15,000 events 
were accounted.
2.6 | Peptide analysis and docking studies
The identified peptide sequences were scanned using 
the Scanner and Reporter of Target-Unrelated Peptides 
(SAROTUP) webserver in order to accurately remove the 
existence of target-unrelated peptides, false positives, and 
existing mimotopes (Huang et  al.,  2010). Then, the se-
quences were analyzed through the Basic Local Alignment 
Search Tool (BLAST) algorithm for homology to proteins 
with known correlation with cancer and, for this purpose, 
the BLAST search program was used against Homo sapiens 
protein database. For the docking studies, a list of SK-BR-3 
biomarkers and cell receptors were retrieved from literature 
(Mota et al., 2017) and the Harmonizome database (Rouillard 
et al., 2016), using “cytoplasmic membrane protein,” “cell 
receptor” and “breast cancer biomarker” as keywords, in 
order to select potential cell surface targets for the sequences 
obtained. The receptors and membrane proteins expressed at 
the SK-BR-3 cell's cytoplasmic membrane were listed tak-
ing into account their high or low expression levels (data not 
shown).
A total of 60 candidates were collected and, afterward, 
a literature search was performed for each of them to select 
only those expressed at the cell surface. This was the starting 
point criterion, since all assays were conducted at 4°C and, 
therefore, no phage internalization was expected. Out of the 
60, 30 candidates satisfied the criterion, according to Uniprot 
database, and are shown in Table  S1. These 30 candidates 
were then used for the subsequent studies, where each of 
the proteins was prepared for protein–ligand docking (Sousa 
et  al.,  2006, 2013), considering a flexible peptide. Protein 
structures were searched in the Protein Data Bank (https://
www.rcsb.org/) (Berman et al., 2000). When more than one 
structure was available for a particular human protein, the se-
lection of the structures to be used was based on some fun-
damental aspects: priority to structures with good resolution 
(bellow 2 Å), absence of mutated residues, and presence of a 
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crystallographic ligand, to be used as reference for a putative 
binding pocket. However, it was not always possible to choose 
a structure with all these characteristics. Of the 30 possible 
protein targets, only 17 had PDB structures (Table S2). For 
the remaining 13 human proteins, a model was retrieved 
from the SWISS-MODEL Repository (Table  S3), a data-
base of annotated 3D protein structure models generated by 
the SWISS-MODEL homology-modeling pipeline (Bienert 
et al., 2017), which has been shown to produce models with 
good accuracy in comparison with the corresponding exper-
imentally determined structures (Waterhouse et  al.,  2018). 
It currently holds over 400,000 high-quality models cover-
ing almost 20% of Swiss-Prot/UniProtKB entries. For each 
protein, structural models were chosen taking into account 
the Global Model Quality Estimation (GMQE) and QMEAN 
(Studer et al., 2020) scores. The first considers the template 
search method and the alignment between the target and the 
template while the latter generates both per residue and global 
quality estimates based on statistical potentials of mean force 
(Studer et al., 2020; Waterhouse et al., 2018) (Table S2).
The structure of Pep1 was created in ChemDraw 19.0 and 
converted from SMILE format with OpenBabel (O'Boyle 
et al., 2011). Partial charges and hydrogen atoms were added 
according to the protonation at physiological pH and the ini-
tial 3D structure was generated and optimized.
Docking was performed with two independent protein–
ligand docking programs considering a flexible peptide: 
GOLD (ChemPLP scoring function) (Jones et al., 1997) and 
AutoDock Vina (Trott & Olson, 2010). The reasoning behind 
the choice of two docking alternatives was to evaluate consis-
tency and cross-validate results. They are widely used tools to 
predict protein–ligand interactions (Sousa et al., 2006, 2013), 
as well as protein–peptide interactions, as recently reviewed 
(Hauser & Windshügel, 2016).
For both programs, initial coordinates for the putative 
binding pocket for each possible target were preferentially 
defined based on known co-crystallized ligands. When there 
was no information about the exact location of a binding 
pocket, Fpocket (Le Guilloux et  al.,  2009), a software for 
ligand pocket detection and characterization was used to 
predict it. The pockets predicted were then analyzed and a se-
lection based on pocket score and Solvent Accessible Surface 
Area was performed. Fpocket has been extensively used 
for binding pocket detection in a variety of targets and has 
shown very good results (Gervasoni et al., 2020; Schmidtke 
& Barril, 2010; Schmidtke et al., 2010). Re-docking was em-
ployed as a validation tool to evaluate the protocols' ability in 
reproducing the orientation and geometry of the co-crystal-
lized ligands.
The peptide was docked into the structures of all the pos-
sible protein targets with GOLD (ChemPLP) and AutoDock 
Vina. Docking conditions for GOLD (ChemPLP) were bind-
ing pocket radius of 15 Å, search efficiency of 150% and the 
number of runs was set to 100. For Vina, the grid box was set 
to 30 Å in all dimensions (x, y, z) and the exhaustiveness of 
the search was set to 100. These conditions are more extreme 
than those typically used in standard protein–ligand dock-
ing protocols (Hauser & Windshügel, 2016; Vieira & Sousa, 
2019), but were chosen to ensure a greater exploration of the 
conformational space of the protein–peptide association and 
a higher accuracy in the predictions. Consistency in the dock-
ing protocol for each software is important to have confidence 
and compare the results. Ranked lists of the most likely pro-
tein targets were obtained with each program. Finally, GOLD 
(ChemPLP) and Vina scoring values were normalized and 
compared and a final ranked list was prepared. The predicted 
protein–peptide conformations were visually inspected and 
analyzed.
2.7 | Statistical analysis
The statistical analysis was performed using GraphPad Prism 
5.03 (GraphPad Software, Inc.). Statistical significance was 
evaluated using one-way ANOVA with Tukey's multiple 
comparison test, with a 95% significance level.
3 |  RESULTS AND DISCUSSION
3.1 | Biopanning identified two peptides 
binding to SK-BR-3 cells
Phage display has been extensively used in the cancer re-
search field (Aghebati-Maleki et  al.,  2016; Bakhshinejad 
et  al.,  2015; Bazan et  al.,  2012; Ferreira et  al.,  2019; 
Nobrega et  al.,  2016; Shukla & Krag,  2005; Sørensen 
et al., 2017). It allows, among others, the use of whole cells 
as targets against a wide range of peptides, without the need 
of previous knowledge of the cells' membrane biochemical 
composition.
In order to isolate specific peptides for the SK-BR-3 cell 
line, the Ph.D.TM – C7C library commercial library was 
used. The biopanning consisted of four rounds for phage 
pool enrichment followed by a counter-selection round with 
control cell line MCF-10-2A. The output (number of recov-
ered plaque-forming phages) divided by the input (number 
of plaque-forming phages from the previous selection round) 
infers the phage binding efficiency after each round. Due to 
titer losses, amplification of the phage pool was conducted 
after round 3 and 4, resulting in a higher input titer (Figure 1). 
These results strongly suggest an enrichment between rounds.
After the counter-selection round, several random individ-
ual clones were isolated, amplified by PCR and selected for 
DNA sequencing, showing two different variant sequences, 
Pep1-CTGNQAAFC and Pep2-CTSLFMNDC, with a hit 
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of 75% for Pep1 and 25% for Pep2. Moreover, these two se-
quences were aligned for the identification of small motif 
sequences and only threonine (T) appeared repeated in the 
second position in both peptides.
3.2 | Binding assays confirm affinity and 
specificity of Pept 1 for SK-BR-3 cells
Phages expressing Pep1-CTGNQAAFC and Pep2-
CTSLFMNDC were used in binding assays, with MCF-
10-2A cells serving as a negative control and BT-474 cells 
to test the peptides' specificity toward the HER2 receptor. 
We observed a significant fluorescence curve shift in the 
histogram of SK-BR-3 cells, for both Pep1 and Pep2, but not 
for other two cell lines (data not shown).
Statistical analysis of the data was performed. Results 
presented in Figure  2 were obtained after subtraction of 
cells' autofluorescence and confirm a high specificity be-
tween SK-BR-3 cells and both Pep1-CTGNQAAFC and 
Pep2-CTSLFMNDC, with p < .0001. This statistical signif-
icance was not observed for MCF-10-2A nor BT-474 cells. 
Moreover, when comparing fluorescence signal between 
the different cell lines for the same peptide, SK-BR-3 cells 
showed an increased signal with statistical significance as 
compared to MCF-10-2A (p < .001) and BT-474 (p < .0001) 
for Pep1. This statistical significance was not observed for 
Pep2 and therefore, the following experiments were con-
ducted only with Pep1.
As no binding to cell line BT-474 was observed, we sus-
pect that the HER2 receptor might not be the target of the 
Pep1, since both cell lines, BT-474 and SK-BR-3, overex-
press this receptor and data analysis only showed statistical 
significance for Pep1 toward the latter one.
3.3 | C5AR1 and CX3CR1 are potential 
targets of Pept 1
From this point on, only the Pep1 sequence was used for bio-
informatics analysis and docking studies. First, the sequence 
was analyzed through the SAROTUP (Huang et  al.,  2010) 
webserver that is the most extensive database for assessing 
peptides derived from phage display protocols, in order to 
remove the existence of false positives and target-unrelated 
peptides (TUPs). The software predicted that the identified 
peptide does not bind to contaminants or other items of the 
selection process, and also that it is a clone without a growth 
propagation advantage, being more likely a true binder with 
high affinity to the target. Moreover, the results also showed 
F I G U R E  1  Phage binding efficiency and phage recovery after in 
vitro biopanning using a disulfide-constrained peptide library against 
SK-BR-3 cells. (a) Enrichment of binding phages for each biopanning 
round and (b) Phage recovery, calculated as the ratio between output 
and input of each biopanning round
F I G U R E  2  Binding ability of Pep1 and Pep2 toward the breast cell lines MCF-10-2A, BT-474 and SK-BR-3 demonstrated by flow cytometry. 
Peptide 1 (Pep1) relates to the variant CTGNQAAFC and peptide 2 (Pep2) relates to the variant CTSLFMNDC. This data is expressed as the 
mean ± SD of three independent experiments. Two-way ANOVA indicates statistically significant differences within the group assessed by Tukey 
post-test and denoted as follows: ****p < .0001, ***p < .001 and ns p > .05 [Colour figure can be viewed at wileyonlinelibrary.com]
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that this sequence does not bear any known TUP motifs and 
no identical peptides in the Biopanning Data Bank (BDB) 
database were found, thus highlighting the novelty of the 
peptide herein selected. To determine its homology with 
previous known cancer-related proteins, the protein–protein 
BLAST analysis was performed and no significant similari-
ties were found.
Docking results are reported in Table S4. A good consis-
tency of the ranked predictions of GOLD and Vina was ob-
tained. After normalizing and comparing the docking scores 
obtained with GOLD (ChemPLP) and Vina, and carefully 
analyzing the binding poses, a selection of the 6 most likely 
protein targets able to interact with Pep1, was made. These 
results are gathered in Table 1, together with the scores for 
ERBB2 (HER2) for comparative purposes.
The ChemPLP scoring function in GOLD uses Piecewise 
Linear Potential to treat van der Waals and repulsive terms. 
It is designed to predict the ligand binding pose rather than 
its binding affinity. It is a dimensionless fitness score, and 
its interpretation is the higher the score, the better the bind-
ing affinity (Verdonk et al., 2003). AutoDock Vina, on the 
other hand, is a mixed empirical and knowledge-based scor-
ing function that divides the binding free energy into several 
terms that describe the protein–ligand interactions and used 
structural information obtained experimentally. It scores the 
poses in a metric that approximates binding free energy pre-
dictions, that is, the more negative the stronger the binding 
affinity (Trott & Olson, 2010).
Overall, the results presented indicate good consistency 
between the two docking programs. Both ChemPLP and 
Vina yielded high scores to Complement component 5a re-
ceptor 1 (C5AR1) and Chemokine (C-X3-C motif) receptor 
1 (CX3CR1). Also, there seems to be a clear prevalence of 
G protein-coupled receptor proteins among the top results. 
Interestingly, HER2 receptor low scores corroborated the hy-
pothesis that this receptor might not be the Pep1 target.
The C5AR1 and CX3CR1, along with Olfactory receptor, 
family 2, subfamily H, member 2 (OR2H2), G protein-cou-
pled receptor 62 (GPR62) and G protein-coupled receptor 
143 (GPR143) are five of the top six scored receptors and all 
belong to the G protein-coupled receptors.
The G protein-coupled family (GPCR) comprise a class 
of proteins that contribute directly in many physiological re-
sponses and have great potential as therapeutic targets for a 
wide range of diseases (Rosenbaum et al., 2009). At a cellular 
level, these proteins regulate cell proliferation, as well as cell 
survival and motility, and have been emerging as indubita-
bly key players in tumor growth, angiogenesis and metasta-
sis (Bar-Shavit et al., 2016; Lappano & Maggiolini, 2012). 
Moreover, these receptors are the most targeted gene family 
for FDA-approved drugs (Sriram et al., 2019).
C5AR1 has been found in tumor cells of several cancers. 
Patients with positive or high expression in lung, breast, 
kidney and gastric cancer showed lower survival rate than 
that of patients with negative expression (Yuxuan,  2019). 
An abnormal expression of this receptor has been associ-
ated with activation of downstream pathways with beneficial 
processes that promotes tumor progression and metastasis 
(Yuxuan, 2019). In relation to breast cancer, the correlation 
between C5AR1 expression in cancer cells and the tumor de-
velopment suggests this receptor might be closely associated 
with breast cancer progression and even could be considered 
as a new target, in particular to triple-negative breast cancer 
(TNBC), despite not being considered a specific biomarker 
(Imamura et al., 2016). On a similar note, CX3CR1 is widely 
associated with several types of cancers, including breast 
cancer, pancreatic cancer, gastric cancer, and colorectal can-
cer (Erreni et al., 2016; Singh, 2010; Wang et al., 2017; Wei 
et al., 2015). It has been shown to play a significant role in 
cancer metastasis, promoting tumor proliferation and mi-
gration, demonstrating both the biological and clinical sig-
nificance of this receptor in breast cancer aggressiveness 
(Singh, 2010). Moreover, it has been suggested that CX3CR1 
could be used as a diagnostic biomarker for pancreatic cancer 
(Wang et al., 2017).
The Isoform short of Insulin Receptor (INSR), which 
is an isoform that can be activated by insulin and insulin 
growth factors 1 and 2, belongs to the receptor tyrosine ki-
nase family of proteins, being the encoded insulin receptor 
preproprotein processed to produce alpha and beta subunits 
to form a heterotetrameric receptor (Boucher et  al.,  2014). 
The insulin signaling pathway is activated through binding of 
insulin or other ligands to this receptor, which regulates glu-
cose uptake and release, as well as the synthesis and storage 
of lipids, carbohydrates and proteins (Boucher et al., 2014). 
Insulin receptor's functions in breast cancer biology have 
T A B L E  1  List of the six proteins that presented the highest 
binding score with Pep1, along with ERBB2 scores, for both docking 
programs and main interacting residues
C5AR1 73.80 −8.4 E27, Y278, K365, 
P356
CX3CR1 66.66 −9.0 Y90, Q164, 
G177, Y179, 
R191
INSR 64.80 −8.3 R1000, R1026, 
A1080, N1097
OR2H2 60.91 −8.6 N82, C177, K270
GPR62 68.11 −7.1 P207, R231, 
R233, G237
GPR143 62.77 −7.6 A61, S67
ERBB2 64.01 −4.2 S728, G729, 
F731, T733, 
R756, D808
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been well-documented (Vigneri et al., 2016), being its con-
tent approximately 80% higher in breast cancer tissues when 
compared to normal breast ones (Papa et al., 1990).
OR2H2 is a membrane olfactory receptor that inter-
acts with odorant molecules in the nose to initiate a neu-
ronal response that triggers the perception of a smell (Lee 
et  al., 2019). This receptor is also expressed in diverse ex-
tra-nasal tissues and is involved in several different biological 
functions. Recently, rather than be only highly specialized 
components of the olfactory sub-genome, these type of re-
ceptors are now considered candidate cancer genes, being 
associated with breast cancer (Ranzani et  al.,  2017; Weber 
et al., 2018).
GPR62 was first identified by Lee et  al.  (2001) and its 
mRNA expression was detected in the basal forebrain, frontal 
cortex, caudate, putamen, thalamus, and hippocampus. Given 
its high expression in brain tissues, it is hypothesized that 
its ligand may be a neurotransmitter (Lee et al., 2001). The 
GPR143 encodes a protein necessary to control the growth of 
melanossomes (Bassi et al., 1995; Schiaffino et al., 1999) and 
in 102 cases of melanoma it was found an enrichment of its 
gene product. It is also a favorable prognostic marker in renal 
and cervical cancer (Uhlen et al., 2010).
Pep1, due to its loop conformation, is very bulky, as such, 
the binding pocket (represented in yellow surface) of the pos-
sible protein target must be big enough to allow interaction. In 
Figure 3, the interaction of the Pep1 with the top 6 potential 
protein candidates is presented in detail. The peptide–protein 
interactions are mainly due to hydrogen bonding between the 
peptide and protein side chains.
C5AR1 presents the highest ChemPLP score and sec-
ond highest Vina score. Pep1 interacts, via salt bridge, 
with Lys365, this is a strong interaction and highly con-
tributes to the stability of Pep1 in the binding pocket. The 
NH2 groups of Pep1 present weak interactions with the 
side chains of two amino acid residues Glu27 and Pro356. 
Finally, the NH group of Tyr278 formed a weak H-bond in-
teraction with Pep1. CX3CR1 was the target that presented 
the highest score for Vina and third highest for ChemPLP. 
Pep1 seems to be buried in the active site. There is the for-
mation of a weak hydrogen bond between Pep1 and the NH 
group of Gln164. Gly177 and Arg191 form H-bonds with 
the NH2 groups of Pep1. Oxygen atoms from Tyr90 and 
Tyr179 side chains show weak H-bond interactions with 
the oxygen groups of the peptide. INSR seems to present 
a pocket that is shallower and closer to the surface of the 
protein. Pep1 interacts via salt bridge with the guanidinium 
((NH2)2
+) group of Arg1000 and Arg1026. It also forms 
H-bonds with Ala1080 and Asn1097. Pep1 interacts with 
three amino acid residues of OR2H2. Lys270 forms salt 
bridges and H-bonds with Pep1, suggesting that this res-
idue may contribute significantly to the Pep1 stability. 
F I G U R E  3  Representation of the binding pocket of the top 6 peptide-docking solutions. Proteins are presented in surface with the active 
site highlighted in yellow. Pep1 is shown in sticks, with carbon atom represented in pink, red for oxygen atom and blue for nitrogen atom. In the 
detailed images, the protein is shown in cartoon and the interacting amino acid residues are displayed in sticks with white carbons, red oxygen, and 
blue nitrogen atoms. The yellow dot lines represent the electrostatic interactions between the peptide and the amino acid residues [Colour figure can 
be viewed at wileyonlinelibrary.com]
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Additionally, Asn82 forms multiple weak hydrogen bonds 
between its side chain and Pep1 and one of its NH2 group 
forms a hydrogen bond with Cys177. GPR62 interacts with 
the NH2 group of Pep1 by forming H-bonds with Pro207, 
Arg231, and Gly237. There is also the formation of a salt 
bridge between Pep1 and the Arg233 residue. Interaction 
of Pep1 with GPR143, on the other hand, is mainly due 
to weak H-bond with Ala61 and Ser67. This might be ex-
plained by the fact that GPR143's pocket is shallower than 
the binding pocket of GPR62.
These results support our experimental data since nei-
ther MCF-10-2A nor BT-474 cell lines express these re-
ceptors or biomarkers, suggesting that at least one of these 
proteins could have a potential role as a targeting receptor 
for Pep1. The docking results guided the selection from 30 
to six possible proteins. The next step would be to experi-
mentally validate the binding of Pep1 to these specific pro-
teins. Finding such targets is important given the current 
state of breast cancer diagnosis. Developing approaches 
that simultaneously allow an accurate early detection with 
minimum discomfort for the patient is urgent and many ef-
forts have been made to introduce the detection of circu-
lating tumor cells as a standardized practice, with several 
studies suggesting different ideas for different breast can-
cer targets (Frithiof et al., 2015; Gilbey et al., 2004; Kruspe 
et al., 2017; Loeian et al., 2019). This is an important step 
that, once in a clinical context, could help identify patients 
at higher risk of developing metastasis in early stages, thus 
allowing oncologists to determine with a better accuracy 
the necessary aggressive treatment and, simultaneously, 
sparing low-risk patients from unnecessary therapies and 
all the side effects that come with them.
4 |  CONCLUSION
Current recognition elements lack the necessary specificity to 
accurately diagnose breast cancer subtypes without invasive 
procedures. Some of the main limitations include having to 
own previous knowledge of the cell's biochemical architec-
ture, presenting variations at their surface, and often cam-
ouflaging the target. Furthermore, the cell's targets are often 
isolated for experimental assays, introducing the possibility 
of a different structural conformation hence making the po-
tential biomarker non-functional in its purpose. Therefore, 
searching for candidates that can target whole cells might be 
a way to narrow down these limitations.
In this work, we identified a novel peptide with specificity 
to the SK-BR-3 breast cancer cell line, through phage display 
biopanning with the help of bioinformatics. These results 
showed selective binding of the peptide (CTGNQAAFC) 
to SK-BR-3 rather than to normal breast cells and another 
breast cancer cell line. Bioinformatics tools predicted C5AR1 
and CX3CR1 as potential biomarkers to which peptide Pep1 
binds. Such peptide was found to be specific for SK-BR-3 
cells and could be a valuable tool for the development of di-
agnostic probes as well as more specific targeted therapeutic 
solutions against this breast cancer subtype.
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